. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: J Low Genit Tract Dis. 2013 Apr;17(5 0 1):S64–S68. doi: 10.1097/LGT.0b013e3182854399

Table 3.

Benchmarking CIN3+ risks for Pap results and HPV test result for ASC-US among women aged 21–24 to risk thresholds implicitly used to determine clinical management options based on screening Pap tests among women aged 30–64.

Current recommended management strategy based on Pap-alone	Implicit risk threshold: 5-year CIN3+ risk by baseline Pap result alone (regardless of HPV result) among women aged 30–64¹			5-year CIN3+ risk by baseline Pap result and HPV test result for ASC-US among women aged 21–24
Current recommended management strategy based on Pap-alone	Management defining result	Frequency in women aged 30–64	CIN3+ risk	HPV/Pap result	Frequency in women aged 21–24	CIN3+ risk
Immediate Colposcopy				HSIL	0.18%	28%
				ASC-H	0.34%	16%
	LSIL	0.97%	5.2%	AGC	0.06%	6.9%

6–12 month return				HPV+/ ASC-US	5.2%	4.4%
	ASC-US	2.8%	2.6%	LSIL	3.6%	3.0%
				ASC-US	8.4%	3.0%

3-year return				HPV-/ ASC-US	2.7%	0.57%
3-year return	Pap-	95.6%	0.26%	Pap-	87.4%	0.20%

Data presented in: Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines J Low Genit Tract Dis In press.